Redeye’s first comments follow this morning’s Q1 report from Tagmaster.
Redeye sees a Q1 report with sales matching our forecasts, strong net customer intake, and a somewha...
Q1 sales in line with est. at SEK 211m, 8% org. growth EBIT in line, and FCF better than expected at...
Redeye provides its comments on Stille following a solid Q1 report, which exceeded our sales estimat...
Redeye notes that Q1 sales were in line with our estimate, and the EBIT was 29% above our forecast.
Redeye comments on Thunderful Group’s preliminary Q1 numbers, which are significantly lower than our...
Sales +10%, EBITDA +13% vs. ABGSCe New ARR definition more comparable with peers Cost base disciplin...
Adj. EBIT SEK -15m (ABGSCe -9m, FactSet cons -5m) Q1 a very small quarter, cons EBIT likely down 1-2...
Redeye states the report beat its estimates on net sales and profitability.
XVIVO delivered an organic growth surprise at 32% (CER) during Q1 a quarter, with a substantial cont...
Redeye’s first take on the Q1 report this morning. Cellavision presented a slightly weaker top line,...
Redeye provides an update following the Q1 2024 report.
There has been a somewhat mixed news flow from Prolight after the close of Q1’24.
Redeye will likely increase its forecasts and Base Case following a strong Q1 report driven by a sig...
Servicebolaget Coor rapporterade i linje med Analysguidens prognos.
Sales +11%, adj. EBITA +16% vs. cons, +8% org. sales Cons to raise '24e adj.
Redeye comments on BioInvent's Q1 report 2024.
Scanfil's Q1 net sales and clean EBIT were below LSEG Data & Analytics consensus.
Scanfil’s Q1 revenue fell more than estimated, which also caused EBIT to drop below estimates, howev...
Redeye updates its estimates and valuation following Lifco releasing its Q1 2024 report, which came ...
